Incretin-based antidiabetics: GLP-1 mimetics and DPP-IV inhibitors

被引：1
|
作者：
Gallwitz, B. [1 ]
机构：
[1] Univ Tubingen, Med Klin & Poliklin, Abt Innere Med 4, Med Klin 4, D-72076 Tubingen, Germany
来源：
DIABETOLOGIE UND STOFFWECHSEL | 2008年 / 3卷 / 04期
关键词：
type; 2; diabetes; antidiabetic drugs; incretins; GLP-1; mimetics; DPP-IV-inhibitors;
D O I：
10.1055/s-2008-1076915
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The effective management of type2 diabetes mellitus continues to pose a challenge to physicians. Despite the use of treatments according to the guidelines, only one third of patients reach the optimal glycemic control target; other goals such as weight loss, often remain unaffected. None of the traditional treatments are able to delay the underlying pathophysiologic defects of type2 diabetes, i.e. progressive beta-cell-dysfunction and insulin resistance. A new class of antidiabetic drugs, the incretin-based therapies (GLP-1 mimetics and DPP-IV-inhibitors), provide an alternative option to currently available hypoglycaemic agents. Particular mention deserves the favourable weight-change profile of the GLP-1 mimetics and their potential P-cell regenerating effect. The present article reviews the profile of these new GLP-1-based therapies, focusing on the two GLP-1-mimetics exenatide and liraglutide.
引用
收藏
页码：234 / +
页数：7
相关论文
共 50 条
  • [21] Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?
    Davies, Melanie J.
    Bianchi, Cristina
    Del Prato, Stefano
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2020, 107
  • [22] Incretin effect: GLP-1, GIP, DPP4
    Kazakos, Kyriakos
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 93 : S32 - S36
  • [23] Incretin mimetics and DPP-IV inhibitors: New paradigms for the treatment of type 2 diabetes (vol 19, pg 612, 2006)
    Hinnen, D.
    Nielsen, L. L.
    Waninger, A.
    Kushner, P.
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2007, 20 (02) : 240 - 240
  • [24] Evaluation of the Serum Levels of the Incretins (GLP-1 and GIP) and DPP-IV in Crohn's Disease
    Magro, Daniela
    Calixto, Antonio
    Vasques, Ana Carolina
    Martinez, Carlos Augusto
    Rossi, Debora Helena
    Geloneze, Bruno
    Pareja, Jose
    Coy, Claudio
    INFLAMMATORY BOWEL DISEASES, 2016, 22 : S58 - S58
  • [25] Acute DPP-IV Inhibition Induces Vascular Relaxation Via GLP-1 Independent Pathways
    Shah, Zubair I.
    Pineda, Colleen A.
    Ying, Zhekang
    Kampfrath, Thomas
    Shah, Nilay
    Deiuliis, Jeffrey
    Sun, Qinghua
    Rajagopalan, Sanjay
    DIABETES, 2010, 59 : A175 - A175
  • [26] Nonlinear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects
    Dai, Haiqinq
    Gustavson, Stephanie M.
    Calle, Roberto A.
    Hirshberg, Boaz
    DIABETES, 2007, 56 : A135 - A136
  • [27] GLP-1 secretion and beneficial effects of DPP-IV inhibition are increased in insulin resistant rats
    Balkan, B
    Li, X
    Kwasnik, L
    DIABETOLOGIA, 2000, 43 : A148 - A148
  • [28] Aminomethylpyridines as DPP-IV inhibitors
    Peters, JU
    Weber, S
    Kritter, S
    Weiss, P
    Wallier, A
    Zimmerli, D
    Boehringer, M
    Steger, M
    Loeffler, BM
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (13) : 3579 - 3580
  • [29] GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
    Holst, Jens Juul
    NATURE METABOLISM, 2024, 6 (10) : 1866 - 1885
  • [30] Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?
    Nauck, M.
    Smith, U.
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 23 (04) : 513 - 523
12345